Related Experiment Video
Updated: Jul 9, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Pharmacotherapy for bronchiectasis
Michael R Loebinger1, Robert Wilson
1Royal Brompton Hospital, Host Defence Unit, Fulham Road, London, SW3 6NP, UK.
Abstract:
Bronchiectasis is a chronic lung disease and clinically is characterised by chronic cough, sputum production and susceptibility to lower respiratory tract infections. Management of bronchiectasis involves investigation to identify treatable causes and then focusing on prevention of exacerbations by regular physiotherapy and the appropriate use of antibiotics for infective exacerbations. There are few good quality, randomised, controlled trials in bronchiectasis and much of the treatment is based on expert opinion and extrapolation from the management of other respiratory conditions. This article discusses the management of bronchiectasis with particular reference to the pathophysiological processes involved in the condition. It then looks at the available evidence supporting such a management plan.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...